Canada

Canada has for over 45 years, had a publicly funded national healthcare system designed to ensure residents receive “reasonable access” to “medically necessary” health-care services, regardless of their financial means. However, unlike many of its European counterparts, Canada has a decentralised system, comprising of 13 separate provincial and territorial health insurance plans. These plans determine how best to organize, manage, and deliver health care within their jurisdictions, guided by common values such as equity and solidarity, and are responsible for meeting basic standards of coverage.


sucroferric oxyhydroxide (Velphoro )

Generic Name: sucroferric oxyhydroxide Brand Name: Velphoro Manufacturer: Vifor Fresenius Medical Care Renal Pharma Indications: Hyperphosphatemia, end-stage renal disease Manufacturer Requested Reimbursement Criteria1: ​The control of serum phosphorus levels in adult patients with end-stage renal disease (ESRD) on dialysis. Submission Type: New Project Status: Pending Call For Patient Input: May […]


crisaborole (TBC )

Generic Name: crisaborole Brand Name: TBC Manufacturer: Pfizer Canada Inc. Indications: atopic dermatitis Manufacturer Requested Reimbursement Criteria1: ​For treatment of mild to moderate atopic dermatitis in patients 2 years of age and older who have failed or are intolerant to a topical corticosteroid treatment. Submission Type: New Project Status: Pending Call […]


rivaroxaban (Xarelto)

Generic Name: rivaroxaban Brand Name: Xarelto Manufacturer: Bayer Inc. Manufacturer Requested Reimbursement Criteria1: ​For use in combination with low-dose ASA, for the prevention of stroke, myocardial infarction and cardiovascular death in patients with concomitant coronary artery disease (CAD) or peripheral artery disease (PAD). Submission Type: New Indication Project Status: Pending […]


Drugs for the Management of Rheumatoid Arthritis

Key Messages For rheumatoid arthritis patients with moderate to severe disease in whom treatment with methotrexate has failed or who are intolerant to methotrexate, conventional synthetic disease-modifying antirheumatic drugs (alone or in combination), biologics (including biosimilars), and targeted synthetic disease-modifying antirheumatic drugs appear to be effective for different outcomes. It […]


fluticasone furoate/vilanterol (Breo Ellipta )

Generic Name: fluticasone furoate/vilanterol Brand Name: Breo Ellipta Manufacturer: GlaxoSmithKline Inc. Indications: Asthma Manufacturer Requested Reimbursement Criteria1: ​After considering the new data from a pragmatic randomized controlled trial representative of everyday clinical practice, Breo Ellipta is clinically more effective and cost-effective at improving asthma control than usual care, which included […]


bictegravir/emtricitabine/tenofovir alafenamide (TBC)

Generic Name: bictegravir/emtricitabine/tenofovir alafenamide Brand Name: TBC Manufacturer: Gilead Sciences Canada, Inc. Indications: HIV-1 infection Manufacturer Requested Reimbursement Criteria1: ​For the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults. Submission Type: New Combination Project Status: Pending Call For Patient Input: April 2, 2018 Patient Input Closed: May 22, 2018 […]


ertugliflozin and metformin (TBC)

Generic Name: ertugliflozin and metformin Brand Name: TBC Manufacturer: Merck Canada Inc. Indications: Diabetes mellitus, Type 2 Manufacturer Requested Reimbursement Criteria1: Added on to metformin for patients who have inadequate glycemic control on metformin and have a contraindication or intolerance to a sulfonylurea, or To replace the individual components of […]


ertugliflozin (TBC)

Generic Name: ertugliflozin Brand Name: TBC Manufacturer: Merck Canada Inc. Indications: Diabetes mellitus, Type 2 Manufacturer Requested Reimbursement Criteria1: As monotherapy for patients who have inadequate glycemic control and for whom metformin or a sulfonylurea is inappropriate due to contraindications or intolerance. Add-on to metformin for patients who have inadequate […]


lixisenatide + insulin glargine (Soliqua)

Generic Name: lixisenatide + insulin glargine Brand Name: Soliqua Manufacturer: sanofi-aventis Canada Inc. Indications: Diabetes mellitus, Type 2 Manufacturer Requested Reimbursement Criteria1: ​As per indication. Submission Type: New Combination Project Status: Pending Call For Patient Input: March 21, 2018 Patient Input Closed: May 10, 2018 Anticipated Date: April 19, 2018 […]


tapentadol hydrochloride (Nucynta)

Generic Name: tapentadol hydrochloride Brand Name: Nucynta Manufacturer: Paladin Labs Inc. Indications: pain, severe Manufacturer Requested Reimbursement Criteria1: For the management of pain severe enough to require daily, continuous, long-term opioid treatment, and: • that is opioid-responsive; and • for which alternative treatment options are inadequate.   Submission Type: New […]


fluocinolone acetonide (Iluvien)

Generic Name: fluocinolone acetonide Brand Name: Iluvien Manufacturer: Knight Therapeutics Inc. Indications: Diabetic macular edema (DME) Submission Type: New Project Status: Active Biosimilar: No Fee Schedule1: Schedule A Key Milestones2 Call for patient input posted3 November 22, 2017 Patient group input closed3 January 18, 2018 Clarification: – No patient input […]


Pegfilgrastim (Lapelga)

Generic Name: Pegfilgrastim Brand Name: Lapelga Manufacturer: Apobiologix Indications: Febrile neutropenia, prevention or treatment Manufacturer Requested Reimbursement Criteria7: As  the preferred pegfilgrastim product to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs. Submission Type: New Project Status: Received Biosimilar: Yes […]


fluticasone furoate/umeclidinium/vilanterol (TBC)

Generic Name: fluticasone furoate/umeclidinium/vilanterol Brand Name: TBC Manufacturer: GlaxoSmithKline Inc. Indications: Chronic obstructive pulmonary disease (COPD) Manufacturer Requested Reimbursement Criteria7: For the long-term, once daily, maintenance treatment of COPD including chronic bronchitis and/or emphysema, in patients with an inadequate response to a LAMA, LABA/LAMA, or ICS/LABA, or currently on multiple […]


ozenoxacin (Ozanex)

Generic Name: ozenoxacin Brand Name: Ozanex Manufacturer: Cipher Pharmaceuticals Inc. Indications: Impetigo Manufacturer Requested Reimbursement Criteria7: ​For the topical treatment of impetigo in patients aged 2 months and older. Submission Type: New Project Status: Received Biosimilar: No Companion Diagnostics: No Fee Schedule1: Pending Submit Feedback Key Milestones2 Call for patient […]


nitisinone (Nitisinone )

Generic Name: nitisinone Brand Name: Nitisinone Manufacturer: Cycle Pharmaceuticals Ltd. Indications: Hereditary tyrosinemia type 1 Manufacturer Requested Reimbursement Criteria7: Hereditary tyrosinemia type 1 Submission Type: New Project Status: Received Biosimilar: No Fee Schedule1: Pending Submit Feedback Key Milestones2 Call for patient input posted3 December 14, 2017 Patient group input closed3 […]


eluxadoline (TBC)

Generic Name: eluxadoline Brand Name: TBC Manufacturer: Allergan Pharma Co. Indications: Irritable bowel syndrom with diarrhea Manufacturer Requested Reimbursement Criteria7: ​For the treatment of IBS-D in adults, as per the proposed indication under review by Health Canada. Submission Type: New Project Status: Pending Call For Patient Input: January 24, 2018 […]


benralizumab (Fasenra)

Generic Name: benralizumab Brand Name: Fasenra Manufacturer: AstraZeneca Canada Inc. Indications: Asthma, severe eosinophilic Manufacturer Requested Reimbursement Criteria7: For add-on maintenance treatment of adult patients with severe eosinophilic asthma who are inadequately controlled with high-dose inhaled corticosteroids (ICS) and one or more additional asthma controller(s) (e.g., LABA), if one of […]


lumacaftor/ivacaftor (Orkambi )

Generic Name: lumacaftor/ivacaftor Brand Name: Orkambi Manufacturer: Vertex Pharmaceuticals (Canada) Incorporated Indications: Cystic Fibrosis, F508del CFTR mutation in patients 6 years and older Manufacturer Requested Reimbursement Criteria7: Treatment of cystic fibrosis (CF) in patients 6 years of age and older who are homozygous for the F508del mutation in the cystic fibrosis […]


ixekizumab (Taltz)

Generic Name: ixekizumab Brand Name: Taltz Manufacturer: Eli Lilly Canada Inc. Indications: Arthritis, psoriatic Manufacturer Requested Reimbursement Criteria7: To be reimbursed for the treatment of adult patients with active psoriatic arthritis (PsA), used alone or in combination with methotrexate, when the response to previous conventional disease-modifying antirheumatic drugs (cDMARDs) therapy […]


Levodopa / carbidopa (Drug Plan Submission) (Duodopa )

Generic Name: Levodopa / carbidopa (Drug Plan Submission) Brand Name: Duodopa Manufacturer: AbbVie Corporation Indications: Parkinson’s disease Requested Reimbursement Criteria: Not applicable. Drug plan submission. Submission Type: Resubmission Project Status: Pending Call For Patient Input: January 11, 2018 Patient Input Closed: March 2, 2018 Anticipated Date: February 8, 2018 Biosimilar: […]